{"id":59055,"date":"2024-02-28T05:40:03","date_gmt":"2024-02-28T05:40:03","guid":{"rendered":"https:\/\/medsname.com\/qutan-sr-400\/"},"modified":"2026-04-30T10:24:04","modified_gmt":"2026-04-30T10:24:04","slug":"qutan-sr-400","status":"publish","type":"product","link":"https:\/\/medsbase.com\/hu\/product\/qutan-sr-400\/","title":{"rendered":"Qutan SR 400"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Gyors v\u00e1lasz<\/h3>\n

Qutan SR 400 (Quetiapine 400 mg SR, extended\/sustained-release) is an atypical antipsychotic for schizophrenia, bipolar mania, bipolar depression, MDD adjunct, and GAD adjunct. Strongly sedating and metabolically heavy \u2014 but uniquely effective for bipolar depression. Often misused as a “sleeping pill” \u2014 discouraged because of metabolic burden.<\/p>\n<\/div>\n

\nMit kapsz a MedsBase-n\u00e1l:<\/strong> WHO-GMP min\u0151s\u00edt\u00e9s\u0171 gy\u00e1rt\u00f3 \u00b7 Diszkr\u00e9t csomagol\u00e1s \u00b7 Vil\u00e1gszerte sz\u00e1ll\u00edt\u00e1s \u00b7 1.400+ hiteles\u00edtett v\u00e1s\u00e1rl\u00f3i v\u00e9lem\u00e9ny<\/a>\n<\/div>\n

\ud83d\udce6 Minden rendel\u00e9st fedez a \u00dajrak\u00fcld\u00e9si Garancia<\/strong><\/a> \u2014 ha a csomagod nem \u00e9rkezik meg 20 munkanapon bel\u00fcl, \u00fajrak\u00fcldj\u00fck.<\/p>\n

Mi\u00e9rt rendelj a MedsBase-r\u00f3l<\/h3>\n

Qutan SR 400 at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our \u00dajrak\u00fcld\u00e9si Garancia<\/a> \u2014 20 \u00fczleti napos \u00e9rkez\u00e9si ablak vagy ingyenes \u00fajrasz\u00e1ll\u00edt\u00e1s \u2014 \u00e9s jogosult a mi h\u0171s\u00e9gprogramunkra<\/a>. .<\/p>\n

What Qutan SR 400 is and how it works<\/h2>\n

Qutan SR 400 is a quetiapine extended\/sustained-release tablet supplied by Cipla. Available strengths: 400 mg SR<\/strong>. Quetiapine has loose D2 binding (rapid dissociation explains low EPS), strong 5-HT2A antagonism, very strong H1 antihistamine action (sedation, weight gain), \u03b11-adrenergic antagonism (orthostasis), and \u03b12 antagonism. Its active metabolite, norquetiapine, has noradrenaline transporter inhibition \u2014 the basis for the antidepressant effect in bipolar depression.<\/p>\n

The SR\/XR formulation is dosed once daily, generally at bedtime. The IR formulation is split BID. SR has slightly lower peak sedation and may be better tolerated for daytime function.<\/p>\n

What Agoprex is and how it works<\/h2>\n\n\n\n\n\n\n\n\n\n\n
Agoprex is a 25 mg agomelatine tablet supplied by Sun Pharma. Agomelatine is mechanistically unique among antidepressants: it acts as an agonist at melatonin MT1 and MT2 receptors and an antagonist at 5-HT2C serotonin receptors. The dual mechanism resynchronises disrupted circadian rhythms (a feature of major depression) while indirectly increasing dopamine and noradrenaline release in the frontal cortex.<\/th>\nAgomelatine has no SERT activity, no anticholinergic effects, and no histaminergic effects \u2014 explaining its very different side-effect profile from SSRIs and TCAs.<\/th>\nIndications and dosing<\/th>\nIndication<\/th>\n<\/tr>\n<\/thead>\n
Schizophrenia (SR)<\/td>\nMax<\/td>\n400\u2013800 mg\/nap<\/td>\n800 mg<\/td>\n<\/tr>\n
Bipolar mania<\/td>\n50 mg BID (IR) or 300 mg HS (SR)<\/td>\n400\u2013800 mg\/nap<\/td>\n800 mg<\/td>\n<\/tr>\n
Bipolar depression<\/td>\nMax<\/td>\n300 mg HS<\/td>\n600 mg<\/td>\n<\/tr>\n
MDD adjunct (SR)<\/td>\nMax<\/td>\n150\u2013300 mg HS<\/td>\n300 mg<\/td>\n<\/tr>\n
GAD adjunct (off-label)<\/td>\nMax<\/td>\n50\u2013150 mg HS<\/td>\n\u2014<\/td>\n<\/tr>\n
Older adults<\/td>\nTarget<\/td>\n50\u2013200 mg\/day<\/td>\ntolerancia alapj\u00e1n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Fontos biztons\u00e1gi megfontol\u00e1sok<\/h2>\n
\nFDA fekete doboz \u2014 demenci\u00e1val \u00f6sszef\u00fcgg\u0151 pszich\u00f3zis<\/strong><\/p>\n

Az \u00f6sszes at\u00edpusos antipszichotikum hordoz egy FDA fekete doboz figyelmeztet\u00e9st a megn\u00f6vekedett hal\u00e1loz\u00e1si kock\u00e1zat miatt (f\u0151leg cardiovascularis \u00e9s fert\u0151z\u00e9ses okokb\u00f3l), amikor id\u0151s, demenci\u00e1ban szenved\u0151 betegek viselked\u00e9szavarainak kezel\u00e9s\u00e9re haszn\u00e1lj\u00e1k. Az at\u00edpusos antipszichotikumok nincsenek j\u00f3v\u00e1hagyva demenci\u00e1val \u00f6sszef\u00fcgg\u0151 pszich\u00f3zis vagy agit\u00e1ci\u00f3 kezel\u00e9s\u00e9re<\/strong>. Haszn\u00e1latuk ebben a popul\u00e1ci\u00f3ban off-label, utols\u00f3 lehet\u0151s\u00e9g, id\u0151korl\u00e1tozott, \u00e9s kifejezett kock\u00e1zat-haszon besz\u00e9lget\u00e9st ig\u00e9nyel.<\/p>\n<\/div>\n

\nHeavy metabolic burden<\/strong><\/p>\n

Weight gain, insulin resistance, dyslipidaemia \u2014 second only to olanzapine and clozapine among atypicals. Mandatory monitoring at baseline, 12 weeks, then 6-monthly: weight, fasting glucose \/ HbA1c, fasting lipids, BP. Counsel about diet\/exercise from initiation.<\/p>\n<\/div>\n

\nOrthostatic hypotension<\/strong><\/p>\n

\u03b11 antagonism produces orthostatic hypotension, particularly in older adults and at initiation. Titrate slowly. Check sitting and standing BP at follow-up.<\/p>\n<\/div>\n

\n“Off-label sleep aid” \u2014 discouraged<\/strong><\/p>\n

Low-dose quetiapine (25\u201350 mg HS) is widely used off-label as a hypnotic. The metabolic burden is the same regardless of indication \u2014 patients on quetiapine for sleep gain weight and develop insulin resistance just as much as patients on quetiapine for psychosis. Dedicated hypnotics (Z-drugs, low-dose doxepin, melatonin agonists, behavioural sleep therapy) are usually safer choices for primary insomnia.<\/p>\n<\/div>\n

\nSuicidality (under-25, MDD adjunct use)<\/strong><\/p>\n

Antidepressz\u00edvumk\u00e9nt t\u00f6rt\u00e9n\u0151 alkalmaz\u00e1skor a 25 \u00e9v alattiakn\u00e1l figyelemmel k\u00eds\u00e9rni kell az \u00f6ngyilkoss\u00e1gi kock\u00e1zatot.<\/p>\n<\/div>\n

Gyakori mell\u00e9khat\u00e1sok<\/h2>\n